Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 4
2007 3
2008 4
2009 3
2010 2
2011 2
2019 1
2020 3
2021 2
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review.
Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, Del Giudice F, Sciarra A, Mariotti G, Gentilucci A. Salciccia S, et al. Among authors: bevilacqua g. Asian J Urol. 2024 Apr;11(2):191-207. doi: 10.1016/j.ajur.2023.01.002. Epub 2023 Feb 6. Asian J Urol. 2024. PMID: 38680577 Free PMC article. Review.
How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy.
Sciarra A, Santarelli V, Salciccia S, Moriconi M, Basile G, Santodirocco L, Carino D, Frisenda M, Di Pierro G, Del Giudice F, Gentilucci A, Bevilacqua G. Sciarra A, et al. Among authors: bevilacqua g. Cancers (Basel). 2024 Feb 13;16(4):764. doi: 10.3390/cancers16040764. Cancers (Basel). 2024. PMID: 38398155 Free PMC article. Review.
Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
Salciccia S, Frisenda M, Tufano A, Di Pierro G, Bevilacqua G, Rosati D, Gobbi L, Basile G, Moriconi M, Mariotti G, Forte F, Carbone A, Pastore A, Cattarino S, Sciarra A, Gentilucci A. Salciccia S, et al. Among authors: bevilacqua g. Clin Genitourin Cancer. 2024 Apr;22(2):74-83. doi: 10.1016/j.clgc.2023.08.008. Epub 2023 Sep 9. Clin Genitourin Cancer. 2024. PMID: 37758559 Free article.
Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
Sciarra A, Santarelli V, Santodirocco L, Frisenda M, Salciccia S, Casale P, Forte F, Mariotti G, Moriconi M, Cattarino S, Sciarra B, Bevilacqua G, Gentilucci A. Sciarra A, et al. Among authors: bevilacqua g. Curr Oncol. 2023 Aug 30;30(9):8054-8067. doi: 10.3390/curroncol30090584. Curr Oncol. 2023. PMID: 37754499 Free PMC article. Review.
Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers' Performance.
Salciccia S, Frisenda M, Bevilacqua G, Gobbi L, Bucca B, Moriconi M, Viscuso P, Gentilucci A, Mariotti G, Cattarino S, Forte F, Fais S, Logozzi M, Sciarra B, Sciarra A. Salciccia S, et al. Among authors: bevilacqua g. Curr Issues Mol Biol. 2023 Jul 21;45(7):6085-6096. doi: 10.3390/cimb45070384. Curr Issues Mol Biol. 2023. PMID: 37504300 Free PMC article. Review.
Comparison of Four Validated Nomograms (Memorial Sloan Kettering Cancer Center, Briganti 2012, 2017, and 2019) Predicting Lymph Node Invasion in Patients with High-Risk Prostate Cancer Candidates for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Clinical Experience and Review of the Literature.
Di Pierro GB, Salciccia S, Frisenda M, Tufano A, Sciarra A, Scarrone E, Del Giudice F, Asero V, Bevilacqua G, Moriconi M, Carbone A, Pastore A, Signore S, Bove P, Forte F, Emiliozzi P, Tubaro A, De Nunzio C, Canale V. Di Pierro GB, et al. Among authors: bevilacqua g. Cancers (Basel). 2023 Mar 9;15(6):1683. doi: 10.3390/cancers15061683. Cancers (Basel). 2023. PMID: 36980571 Free PMC article.
DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives.
Sciarra A, Fiori C, Del Giudice F, DI Pierro G, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G, Salciccia S. Sciarra A, et al. Among authors: bevilacqua g. Minerva Urol Nephrol. 2022 Dec;74(6):649-652. doi: 10.23736/S2724-6051.22.05185-0. Minerva Urol Nephrol. 2022. PMID: 36629806 Free article. No abstract available.
How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
Sciarra A, Frisenda M, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G, Del Giudice F, Di Pierro GB, Viscuso P, Casale P, Chung BI, Autorino R, Crivellaro S, Salciccia S. Sciarra A, et al. Among authors: bevilacqua g. Int J Mol Sci. 2022 Dec 30;24(1):674. doi: 10.3390/ijms24010674. Int J Mol Sci. 2022. PMID: 36614122 Free PMC article. Review.
Comparative Prospective and Longitudinal Analysis on the Platelet-to-Lymphocyte, Neutrophil-to-Lymphocyte, and Albumin-to-Globulin Ratio in Patients with Non-Metastatic and Metastatic Prostate Cancer.
Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, Del Giudice F, Carbone A, Pastore A, Chung BI, Eisenberg ML, Autorino R, Crivellaro S, Forte F, Sciarra A, Mariotti G, Gentilucci A. Salciccia S, et al. Among authors: bevilacqua g. Curr Oncol. 2022 Dec 3;29(12):9474-9500. doi: 10.3390/curroncol29120745. Curr Oncol. 2022. PMID: 36547159 Free PMC article.
Can we reduce worldwide neonatal mortality?
Parmigiani S, Bevilacqua G. Parmigiani S, et al. Among authors: bevilacqua g. Acta Biomed. 2022 Oct 26;93(5):e2022294. doi: 10.23750/abm.v93i5.13225. Acta Biomed. 2022. PMID: 36300225 Free PMC article.
37 results